RELEASE OF NOREPINEPHRINE AND DOPAMINE FROM BRAIN VESICULAR PREPARATIONS: EFFECTS OF CALCIUM ANTAGONISTSEBSTEIN RP; DALY JW.1982; CELL. MOL. NEUROBIOL.; ISSN 0272-4340; USA; DA. 1982; VOL. 2; NO 3; PP. 205-213; BIBL. 18 REF.Article

RELEASE OF NOREPINEPHRINE AND DOPAMINE FROM BRAIN VESICULAR PREPARATIONS: EFFECTS OF ADENOSINE ANALOGUESEBSTEIN RP; DALY JW.1982; CELL. MOL. NEUROBIOL.; ISSN 0272-4340; USA; DA. 1982; VOL. 2; NO 3; PP. 193-204; BIBL. 2 P.Article

DOPAMINE RECEPTOR CHANGES AFTER LONG-TERM HALOPERIDOL TREATMENT IN RATSEBSTEIN RP; PICKHOLZ D; BELMAKER RH et al.1979; J. PHARM. PHARMACOL.; GBR; DA. 1979; VOL. 31; NO 8; PP. 558-559; BIBL. 16 REF.Article

THE EFFECT OF LI ON THE GLUCAGON-SENSITIVE ADENYLATE CYCLASE IN VIVO IN MAN.EBSTEIN RP; KARA T; BELMAKER RH et al.1977; ACTA PHARMACOL. TOXICOL.; DANEM.; DA. 1977; VOL. 41; NO 1; PP. 80-83; BIBL. 1 P.Article

INDIVIDUAL DIFFERENCES IN THE RESPONSE OF DOPAMINE RECEPTOR NUMBER TO CHRONIC HALOPERIDOL TREATMENTBANNET J; BELMAKER RH; EBSTEIN RP et al.1981; BIOL. PSYCHIATRY; ISSN 0006-3223; USA; DA. 1981; VOL. 16; NO 11; PP. 1059-1065; BIBL. 16 REF.Article

THE EFFECT OF LITHIUM ON NORADRENALINE-INDUCED CYCLIC AMP ACCUMULATION IN RAT BRAIN: INHIBITION AFTER CHRONIC TREATMENT AND ABSENCE OF SUPERSENSITIVITYEBSTEIN RP; HERMONI M; BELMAKER RH et al.1980; J. PHARMACOL. EXPER. THERAPEUT.; USA; DA. 1980; VOL. 213; NO 1; PP. 161-167; BIBL. 61 REF.Article

EFFECT OF LITHIUM ON THE PHYSOSTIGMINE-INDUCED BEHAVIORAL SYNDROME AND PLASMA CYCLIC GMPOPPENHEIM G; EBSTEIN RP; BELMAKER RH et al.1979; J. PSYCHIATR. RES.; GBR; DA. 1979; VOL. 15; NO 2; PP. 133-138; BIBL. 25 REF.Article

THE EFFECT OF DRUG HOLIDAYS IN AN ANIMAL MODEL OF TARDIVE DYSKINESIABANNET J; BELMAKER RH; EBSTEIN RP et al.1980; PSYCHOPHARMACOLOGY; DEU; DA. 1980; VOL. 69; NO 2; PP. 223-224; BIBL. 9 REF.Article

D-AMPHETAMINE INHIBITION OF PLATELET MAO FROM SCHIZOPHRENIC PATIENTS.RECHES A; EBSTEIN RP; BELMAKER RH et al.1977; BIOL. PSYCHIATRY; U.S.A.; DA. 1977; VOL. 12; NO 5; PP. 655-659; BIBL. 1 P. 1/2Article

HALOPERIDOL AND LITHIUM BLOCKING OF THE MOOD RESPONSE TO INTRAVENOUS METHYLPHENIDATE.WALD D; EBSTEIN RP; BELMAKER RH et al.1978; PSYCHOPHARMACOLOGY; GERM.; DA. 1978; VOL. 57; NO 1; PP. 83-87; BIBL. 25 REF.Article

THE DIFFERENTIAL EFFECT OF LITHIUM ON NORADRENALINE- AND DOPAMINE-SENSITIVE ACCUMULATION OF CYCLIC AMP IN GUINEA PIG BRAIN.RECHES A; EBSTEIN RP; BELMAKER RH et al.1978; PSYCHOPHARMACOLOGY; DEU; DA. 1978; VOL. 58; NO 2; PP. 213-216; BIBL. 28 REF.Article

RELEASE OF NOREPINEPHRINE FROM BAIN VESICULAR PREPARATIONS: EFFECTS OF AN ADENYLATE CYCLASE ACTIVATOR, FORSKOLIN, AND A PHOSPHODIESTERASE INHIBITOREBSTEIN RP; SEAMON K; CREVELING CR et al.1982; CELL. MOL. NEUROBIOL.; ISSN 0272-4340; USA; DA. 1982; VOL. 2; NO 3; PP. 179-192; BIBL. 2 P.Article

CHRONIC RUBIDIUM DOES NOT PREVENT DOPAMINE RECEPTOR SUPERSENSITIVITYBANNET J; EBSTEIN RP; HERSHKOWITZ M et al.1982; NEUROPSYCHOBIOLOGY; ISSN 0302-282X; CHE; DA. 1982; VOL. 8; NO 6; PP. 281-283; BIBL. 10 REF.Article

LACK OF BENEFIT FROM MAGNESIUM IN LITHIUM TOXICITYZOHAR J; SPIRO D; NOVACK A et al.1982; NEUROPSYCHOBIOLOGY; ISSN 0302-282X; CHE; DA. 1982; VOL. 8; NO 1; PP. 10-11; BIBL. 8 REF.Article

PURIFICATION AND IMMUNOCHEMICAL CHARACTERIZATION OF DOPAMINE BETA -HYDROXYLASE FROM HUMAN PHEOCHROMOCYTOMA.PARK DH; KASHIMOTO T; EBSTEIN RP et al.1976; MOLEC. PHARMACOL.; U.S.A.; DA. 1976; VOL. 12; NO 1; PP. 73-81; BIBL. 33 REF.Article

THE EFFECT OF HALOPERIDOL ON EPINEPHRINE-STIMULATED ADENYLATE CYCLASE IN HUMANS.BELMAKER RH; EBSTEIN RP; SCHOENFELD H et al.1976; PSYCHOPHARMACOLOGY; GERM.; DA. 1976; VOL. 49; NO 2; PP. 215-217; BIBL. 18 REF.Article

THE EFFECT OF L-DOPA AND PROPRANOLOL ON HUMAN CSF CYCLIC NUCLEOTIDES.BELMAKER RH; EBSTEIN RP; STERN R et al.1978; PSYCHOPHARMACOLOGY; DEU; DA. 1978; VOL. 58; NO 3; PP. 307-310; BIBL. 20 REF.Article

A FAMILIAL STUDY IN SERUM DOPAMINE-BETA -HYDROXYLASE LEVELS IN TORSION DYSTONIA = UNE ETUDE FAMILIALE DES TAUX SERIQUES DE DOPAMINE-BETA -HYDROXYLASE AU COURS DE LA DYSTONIE DE TORSIONEBSTEIN RP; FREEDMAN LS; LIEBERMAN A et al.1974; NEUROLOGY; U.S.A.; DA. 1974; VOL. 24; NO 7; PP. 684-687; BIBL. 10REF.Article

HALOPERIDOL BLOOD LEVELS DURING DOSAGE REDUCTION IN CHRONIC SCHIZOPHRENIC PATIENTSGOLDMAN Z; EBSTEIN RP; LERER B et al.1981; NEUROPSYCHOBIOLOGY; ISSN 0302-282X; CHE; DA. 1981; VOL. 7; NO 6; PP. 281-284; BIBL. 12 REF.Article

CHRONIC LITHIUM TREATMENT AND DOPAMINE-MEDIATED BEHAVIOREBSTEIN RP; ELIASHAR S; BELMAKER RH et al.1980; BIOL. PSYCHIATRY; ISSN 0006-3223; USA; DA. 1980; VOL. 15; NO 3; PP. 459-467; BIBL. 2 P.Article

THE EFFECT OF PROPRANOLOL TREATMENT IN SCHIZOPHRENIA ON CSF AMINE METABOLITES AND PROLACTINBELMAKER RH; EBSTEIN RP; DASBERG H et al.1979; PSYCHOPHARMACOLOGY; DEU; DA. 1979; VOL. 63; NO 3; PP. 293-296; BIBL. 23 REF.Article

DOPAMINE RECEPTORS IN A RAT MODEL OF MINIMAL BRAIN DYSFUNCTIONEISENBERG J; BRECHER FRIDE E; WEIZMAN R et al.1982; NEUROPSYCHOBIOLOGY; ISSN 0302-282X; CHE; DA. 1982; VOL. 8; NO 3; PP. 151-155; BIBL. 15 REF.Article

LACK OF EFFECT OF BETA-2 ADRENERGIC STIMULATION ON HUMAN PROLACTINBANNET J; LERER B; EBSTEIN RP et al.1981; PSYCHONEUROENDOCRINOLOGY; ISSN 0306-4530; GBR; DA. 1981; VOL. 6; NO 2; PP. 177-179; BIBL. 20 REF.Article

GAMMA-AMINOBUTYRIC ACID (GABA) IN THE CSF OF SCHIZOPHRENIC PATIENTS BEFORE AND AFTER NEUROLEPTIC TREATMENT.LICHTSHTEIN D; DOBKIN J; EBSTEIN RP et al.1978; BRIT. J. PSYCHIATRY; G.B.; DA. 1978-02; VOL. 132; PP. 145-148; BIBL. 18 REF.Article

SERUM AND CSF LEVELS OF HALOPERIDOL BY RADIOIMMUNOASSAY AND RADIORECEPTOR ASSAY DURING HIGH-DOSE THERAPY OF RESISTANT SCHIZOPHRENIC PATIENTSRIMON R; AVERBUCH I; ROZICK P et al.1981; PSYCHOPHARMACOLOGIA; ISSN 0033-3158; DEU; DA. 1981; VOL. 73; NO 2; PP. 197-199; BIBL. 12 REF.Article